ABT vs CATY · P/E 25, rev $44.33B vs P/E 12, rev $30.4M
Abbott Laboratories (ABT) versus Cathay General Bancorp (CATY) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Cathay General Bancorp (CATY) is a banks - regional company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported CATY revenue for 2026-06-30 was $30.4M. Net income was $179.1M. CATY currently screens at market cap $3.90B and trailing P/E 12.0.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. CATY currently screens at market cap $3.90B and trailing P/E 12.0.
Not investment advice. Open the ABT and CATY stock pages for the full models.
Not investment advice.